FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma
April 1, 2023
On March 22, 2023, the Food and Drug Administration granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte Corporation) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This agent joins avelumab and pembrolizumab as approved therapies for MCC. It targets PD1 and is dosed once per four weeks. Dr. Shailender Bhatia is senior author on the study that was presented at the SITC meeting in 2021, but has not yet been published in a peer-reviewed journal.